Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
- Pritchard-Jones, Kathy
- Bergeron, Christophe
- de Camargo, Beatriz
- van den Heuvel-Eibrink, Marry M
- Acha, Tomas
- Godzinski, Jan
- Oldenburger, Foppe
- Boccon-Gibod, Liliane
- Leuschner, Ivo
- Vujanic, Gordan
- Sandstedt, Bengt
- de Kraker, Jan
- van Tinteren, Harm
- Graf, Norbert
- Ansari Djaberi, Marc Georges
- SIOP Renal Tumours Study Group
DOIAbstract
Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III, histological intermediate-risk Wilms' tumour when a newly defined high-risk blastemal subtype was excluded from randomisation
Add to ORKG